Stephens Inc. AR Has $238,000 Holdings in Hologic, Inc. (NASDAQ:HOLX)

Stephens Inc. AR lessened its stake in Hologic, Inc. (NASDAQ:HOLX) by 14.5% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,845 shares of the medical equipment provider’s stock after selling 651 shares during the quarter. Stephens Inc. AR’s holdings in Hologic were worth $238,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in HOLX. Norges Bank acquired a new position in Hologic in the 4th quarter valued at approximately $133,414,000. Champlain Investment Partners LLC acquired a new position in Hologic in the 4th quarter valued at approximately $79,291,000. Redwood Wealth Management Group LLC acquired a new position in Hologic in the 1st quarter valued at approximately $3,534,000. Northern Trust Corp increased its stake in Hologic by 26.9% in the 4th quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider’s stock valued at $226,898,000 after buying an additional 668,086 shares during the period. Finally, Invesco Ltd. increased its stake in Hologic by 16.4% in the 4th quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider’s stock valued at $293,434,000 after buying an additional 572,187 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Insiders Place Their Bets

In other Hologic news, Director Martin D. Madaus bought 5,445 shares of Hologic stock in a transaction dated Wednesday, May 7th. The shares were bought at an average price of $55.24 per share, with a total value of $300,781.80. Following the purchase, the director owned 5,445 shares of the company’s stock, valued at $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 1.88% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on HOLX. Evercore ISI upped their price objective on shares of Hologic from $62.00 to $68.00 and gave the company an “in-line” rating in a research note on Tuesday, July 8th. Royal Bank Of Canada decreased their target price on shares of Hologic from $75.00 to $70.00 and set a “sector perform” rating for the company in a research report on Friday, May 2nd. Mizuho boosted their target price on shares of Hologic from $65.00 to $70.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 16th. Wall Street Zen downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday, May 5th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Hologic in a research report on Tuesday, May 27th. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Hologic presently has a consensus rating of “Hold” and a consensus target price of $77.33.

Hologic Trading Down 0.0%

Shares of HOLX stock opened at $63.99 on Monday. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.67. The stock has a market cap of $14.26 billion, a price-to-earnings ratio of 27.00, a P/E/G ratio of 2.35 and a beta of 0.55. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.52 and a current ratio of 3.24. The firm has a fifty day moving average of $62.46 and a 200-day moving average of $63.12.

Hologic (NASDAQ:HOLX) last announced its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The firm’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter last year, the company posted $1.03 EPS. On average, equities research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.